Eris Lifesciences Limited has informed the Exchange regarding Resignation of Statutory Auditor of material subsidiary of the Company w.e.f. August 12, 2025.
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eris Lifesciences has informed the exchanges that M/s R R S & Associates (FRN: 118336W), the statutory auditor of its wholly owned material subsidiary Eris Therapeutics Limited, has resigned effective August 12, 2025. The auditor was originally appointed in September 2022 for a five-year term ending March 31, 2027, and had already completed the FY25 audit and the Q1 FY26 limited review before stepping down. The reason given is the appointment of a single common auditor for the holding company and its material subsidiary, to bring in synergies, align terms, and maintain consistency in the audit process. The auditor confirmed there are no other material reasons, no concerns with management, and no issues with the financial statements.
This is a routine administrative reshuffle of auditors driven by a change at the holding company level, with the subsidiary auditor voluntarily ceding to allow a single group auditor. No governance red flags, no audit qualifications, and no disputes were reported, so the impact on shareholders or the stock is expected to be neutral.